These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10261791)

  • 1. Controlling moxalactam and cefotaxime use with a target drug program.
    Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG
    Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs.
    Abramowitz PW; Nold EG; Hatfield SM
    Am J Hosp Pharm; 1982 Jul; 39(7):1176-80. PubMed ID: 7114059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of clinical pharmacists to cefazolin utilization.
    Witte KW; Hatoum HT; Hoon TJ
    Hosp Formul; 1987 Aug; 22(8):737-41. PubMed ID: 10283405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost containment through restriction of cephalosporins.
    Britton HL; Schwinghammer TL; Romano MJ
    Am J Hosp Pharm; 1981 Dec; 38(12):1897-900. PubMed ID: 7325168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic surveillance: the results of a clinical pharmacy intervention program.
    Capers CC; Bess DT; Branam AC; Falbe WJ; Mrochek SA; Haymond JD; Stahl AA
    Hosp Pharm; 1993 Mar; 28(3):206-10, 212. PubMed ID: 10124947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring antibiotic prescriptions can reduce use and cost of drugs.
    Douglas AS
    Mod Healthc; 1984 Oct; 14(13):106-7. PubMed ID: 10268397
    [No Abstract]   [Full Text] [Related]  

  • 8. Savings achieved through cephalosporin surveillance.
    Katz E; Schlamowitz S
    Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods of controlling cephalosporin use in Canadian hospitals.
    Godin JP; Sketris IS; Merrett RA; Marrie TJ
    Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy-laboratory interactions: a unique method to control antibiotic costs.
    Goff D; Thornton J
    Hosp Pharm; 1989 Jan; 24(1):26-9, 32. PubMed ID: 10291600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial impact of formulary revision of second-generation cephalosporins.
    Andrews JD; Hafting S
    Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUE (drug usage evaluation) of ticarcillin and clavulanate potassium: determining appropriate and cost-effective therapeutic options.
    Lomaestro BM; Lesar TS
    Hosp Formul; 1988 Nov; 23(11):909. PubMed ID: 10312767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A strategy to reduce drug expenditures with a drug utilization review program.
    Hoffmann RP
    Hosp Pharm; 1984 Jan; 19(1):7-8, 11-2. PubMed ID: 10264746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
    Hayman JN; Sbravati EC
    Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate but not cost effective ceftazidime use in a university hospital.
    Colburn PA; Carver PA; Montgomery PA; Alaniz C; Chaffee BW; Amesbury BK
    Hosp Pharm; 1989 Nov; 24(11):911-6, 928. PubMed ID: 10313376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy.
    Caldwell RD; Davis SK
    Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antibiotic order form guiding rational use of expensive drugs on cost containment.
    Sirinavin S; Suvanakoot P; Sathapatayavongs B; Malatham K
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):636-42. PubMed ID: 10437971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of an antibiotic cost containment measure.
    Jung B; Andrews JD
    Can J Hosp Pharm; 1990 Jun; 43(3):116-22. PubMed ID: 10105649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible savings with appropriate antibiotic prophylaxis.
    Hodgson T; Lannigan R; Mills D
    Can J Hosp Pharm; 1984; 37(3):95-7. PubMed ID: 10268247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacy initiatives to reduce clindamycin use.
    Greene SA; Record KE; Rapp RP; Amerson AB; Bell RM; Piecoro JJ
    Am J Hosp Pharm; 1986 May; 43(5):1210-3. PubMed ID: 3717177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.